Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program.

Andreoni Massimo,Cacopardo Bruno,Angiola Spinetti,Vanni Borghi,Andrea Antinori,Nicola Boffa,Antonio Di Biagio,Gloria Taliani,Daniela Segala,Giustino Parruti,Vincenzo Vullo,Raffaele Bruno,Massimo Puoti,Sara Bigoni,Antonio Chirianni,Giuliano Rizzardini,Laura Milazzoi,Alfredo Pennica,Andrea De Luca,Giovanni Di Perri,Elisabetta Teti,Loredana Sarmati,Andrea Giacometti,Annalisa Saracino,Andrea Gori,Claudio Maria Mastroianni,Hamid Hasson,C Pasquazzi ,S Sollima ,Anna María Cattelan ,Antonella D’arminio Monforte ,Simit

doi:10.1093/cid/ciw846

Abstract

Patients co-infected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) are at high risk of liver disease progression. We report a favorable safety profile and SVR12 rates of 96.7% among HIV/HCV co-infected patients participating in an Italian compassionate-use program of ombitasvir/paritaprevir/ritonavir + dasabuvir (OBV/PTV/r + DSV) ± ribavirin (RBV).

Full Text